deltatrials
Completed PHASE2/PHASE3 NCT02819635

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Sponsor: AbbVie

Conditions Ulcerative Colitis (UC)
Interventions Placebo Upadacitinib
Updated 31 times since 2017 Last updated: Jun 3, 2022 Started: Sep 26, 2016 Primary completion: Dec 13, 2021 Completion: Dec 13, 2021

A PHASE2/PHASE3 clinical study on Ulcerative Colitis (UC), this trial is completed. The trial is conducted by AbbVie and has accumulated 31 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

31 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  5. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

    Phase: PHASE3 → PHASE2_PHASE3

▶ Show 26 earlier versions

  1. Feb 2022 — Jul 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  4. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  6. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  7. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  8. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  9. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  10. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  11. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  12. Nov 2019 — Mar 2020 [monthly]

    Recruiting PHASE3

  13. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  14. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  15. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  16. Nov 2018 — Apr 2019 [monthly]

    Recruiting PHASE3

  17. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  18. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  19. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

    Phase: PHASE2 → PHASE3

  20. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE2

  21. Nov 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

  22. Sep 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  23. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  24. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  25. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  26. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain, Abiko-shi, Japan, Albuquerque, United States, Almada, Portugal, Alor Star, Malaysia, Amiens, France, Ampang, Malaysia, Amsterdam, Netherlands, Ann Arbor, United States, Arlington, United States and 380 more location s